Magnus Medical, Inc. discovered individualised, rapid-acting, non-invasive neurostimulation technology for the treatment of major depressive disorder (MDD). It is designed for people who have not shown sufficient results after undergoing antidepressant medication or other treatments.
This innovative new therapy is supposed to be the game changer for millions of people suffering from resistant depression. Moreover, it has the ability to manage the depressive symptoms acutely.
Treatment-resistant depression causes human suffering and it is essential to find the effective solution. Hence, the accelerated treatment enables people by offering treatment-resistant depression and managing their symptoms highly and helps to stay well for a lifetime.
This rapidly acting non-invasive neurostimulation technology greatly improves critical unmet need in psychiatric disorders and offers a promising, transformative solution and provides quality of life for millions of people suffering from intractable depression.
US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for individualised treatment of major depression disorders.